BMT stands for bone marrow transplant, a procedure that replaces damaged or destroyed blood-forming stem cells with healthy ones. It’s used to treat blood cancers like leukemia and lymphoma, as well as certain immune system and bone marrow disorders. The procedure itself isn’t surgery in the traditional sense. Healthy stem cells are infused into the bloodstream through a central line, similar to a blood transfusion, and they travel to the bone marrow where they begin producing new blood cells.
Why a Bone Marrow Transplant Is Needed
Your bone marrow is the spongy tissue inside bones that produces red blood cells, white blood cells, and platelets. When disease or intensive cancer treatment destroys this tissue, the body loses its ability to make the blood cells it needs to carry oxygen, fight infection, and control bleeding.
A BMT gives the body a fresh supply of stem cells capable of rebuilding the blood and immune system. For cancers like leukemia or lymphoma, the transplant serves a dual purpose: it allows doctors to use extremely high doses of chemotherapy or radiation to kill cancer cells (doses that would otherwise permanently destroy the bone marrow), and then restores the marrow’s function afterward. BMT is also used for non-cancerous conditions like severe aplastic anemia and certain inherited immune deficiencies.
Types of Bone Marrow Transplant
There are two main types, defined by where the stem cells come from.
In an autologous transplant, you are your own donor. Stem cells are collected from your blood or bone marrow before you undergo high-dose treatment, then frozen and returned to your body afterward. This approach works well when the marrow itself isn’t diseased and the goal is simply to rescue it after aggressive chemotherapy.
In an allogeneic transplant, the stem cells come from another person. That donor might be a sibling, a parent, or an unrelated volunteer found through a registry. A rare subtype, called a syngeneic transplant, uses cells from an identical twin, which eliminates the risk of immune rejection.
How Donor Matching Works
For allogeneic transplants, the donor’s tissue type needs to closely match the recipient’s. This match is determined by a set of proteins on cell surfaces called HLA markers. Doctors test at least four key markers, and the ideal unrelated donor matches on all eight copies (since you inherit one copy from each parent). An 8-out-of-8 match gives the best outcomes, with higher overall survival and lower risk of complications.
When a perfect match isn’t available, a 7/8 match from an unrelated donor can be considered with acceptable risk. For siblings, a 6/6 match at the three most critical markers is the standard. Even a half-matched (haploidentical) family member, sharing just one inherited set of markers, can serve as a donor with modern techniques. This has dramatically expanded the pool of potential donors, since nearly every patient has at least one haploidentical relative, typically a parent or sibling.
The Conditioning Phase
Before the transplant, you go through a preparation phase called conditioning. This involves high-dose chemotherapy, full-body radiation, or a combination of both. The conditioning phase serves two purposes: it suppresses the immune system enough to prevent the body from rejecting the new cells, and in cancer patients, it destroys as many remaining cancer cells as possible.
Traditional conditioning uses very intense doses and is effective but carries significant side effects, including nausea, fatigue, mouth sores, and temporary hair loss. For older patients or those with other health conditions, doctors may use reduced-intensity conditioning, which relies on lower doses to suppress the immune system while causing less damage to organs. This has made transplants accessible to patients who previously wouldn’t have been candidates.
What Happens on Transplant Day
Transplant day is called “Day 0” in the treatment timeline. The stem cells are infused through a central line, the same type of IV catheter used for chemotherapy. The infusion is painless, you stay awake the entire time, and the process resembles a standard blood transfusion more than it does an operation. Once in the bloodstream, the stem cells naturally migrate to the bone marrow spaces inside your bones, where they begin to grow.
Engraftment and Early Recovery
The first 30 days after transplant are the most critical. During this window, the donated cells start to grow and produce new blood cells, a milestone called engraftment. Until engraftment happens, your blood counts remain dangerously low, leaving you highly vulnerable to infections and bleeding. Most patients stay in the hospital or visit the transplant center daily during this period, often in a protected environment with filtered air and strict hygiene protocols.
As engraftment takes hold, blood counts gradually rise. White blood cells return first, signaling that the new immune system is starting to function. The process is gradual, and full immune recovery can take months to over a year.
Graft-Versus-Host Disease
The most significant complication unique to allogeneic transplants is graft-versus-host disease (GVHD). This happens when the donor’s immune cells recognize the recipient’s body as foreign and attack it. The skin, liver, and digestive tract are the most commonly affected organs.
Acute GVHD typically develops in the first few months. Historically, moderate-to-severe cases occurred in nearly half of allogeneic transplant recipients. Advances in donor matching, conditioning regimens, and preventive medications have brought that rate down significantly. Recent data show the incidence of moderate-to-severe acute GVHD has dropped to around 16% at experienced transplant centers. Severe cases, which can be life-threatening, now occur in roughly 4% of patients.
Chronic GVHD can develop later, sometimes months or even years after transplant. It resembles autoimmune conditions, causing dry eyes, skin changes, joint stiffness, or lung problems. It requires long-term management but, notably, carries a secondary benefit: the same immune response that causes GVHD also attacks any residual cancer cells, an effect called graft-versus-tumor.
Long-Term Health After BMT
Surviving the transplant is a major milestone, but long-term follow-up is essential. Studies show that even 10 to 30 years after transplant, survivors face higher rates of secondary cancers, infections, and organ problems compared to the general population. The conditioning treatments that save lives can also leave lasting effects on the heart, lungs, thyroid, eyes, and bones.
Cataracts are common after radiation-based conditioning. Thyroid function can decline, requiring hormone replacement. Heart and blood vessel health needs ongoing attention because the chemotherapy drugs used in conditioning can increase cardiovascular risk. Lung complications, including chronic airway inflammation, affect some patients and require monitoring with breathing tests.
The recommended follow-up schedule is thorough. In the first year, most organ systems are evaluated at six months and again at one year. After that, annual checkups covering eyes, lungs, heart, kidneys, thyroid, liver, and mental health become the standard. Screening for secondary cancers is part of every yearly visit, with particular attention to skin cancers and cancers of the mouth, since these occur at higher rates in transplant survivors. Psychosocial support and sexual health assessments are also built into long-term care plans, recognizing that the transplant experience affects far more than blood counts.